Cargando…
Curbing COVID-19 progression and mortality with traditional Chinese medicine among hospitalized patients with COVID-19: A propensity score-matched analysis
BACKGROUND: Viral- and host-targeted traditional Chinese medicine (TCM) formulae NRICM101 and NRICM102 were administered to hospitalized patients with COVID-19 during the mid-2021 outbreak in Taiwan. We report the outcomes by measuring the risks of intubation or admission to intensive care unit (ICU...
Autores principales: | Tseng, Yu-Hwei, Lin, Sunny Jui-Shan, Hou, Sheng-Mou, Wang, Chih-Hung, Cheng, Shun-Ping, Tseng, Kung-Yen, Lee, Ming-Yung, Lee, Shen-Ming, Huang, Yi-Chia, Lin, Chien-Jung, Lin, Chi-Kuei, Tsai, Tsung-Lung, Lin, Chen-Shien, Cheng, Ming-Huei, Fong, Tieng-Siong, Tsai, Chia-I., Lu, Yu-Wen, Lin, Jung-Chih, Huang, Yi-Wen, Hsu, Wei-Chen, Kuo, Hsien-Hwa, Wang, Li-Hsiang, Liaw, Chia-Ching, Wei, Wen-Chi, Tsai, Keng-Chang, Shen, Yuh-Chiang, Chiou, Wen-Fei, Lin, Jaung-Geng, Su, Yi-Chang |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
The Authors. Published by Elsevier Ltd.
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9395232/ https://www.ncbi.nlm.nih.gov/pubmed/36007774 http://dx.doi.org/10.1016/j.phrs.2022.106412 |
Ejemplares similares
-
A traditional Chinese medicine formula NRICM101 to target COVID-19 through multiple pathways: A bedside-to-bench study
por: Tsai, Keng-Chang, et al.
Publicado: (2021) -
Targeting spike protein-induced TLR/NET axis by COVID-19 therapeutic NRICM102 ameliorates pulmonary embolism and fibrosis
por: Wei, Wen-Chi, et al.
Publicado: (2022) -
NRICM101 ameliorates SARS-CoV-2–S1-induced pulmonary injury in K18-hACE2 mice model
por: Wei, Wen-Chi, et al.
Publicado: (2023) -
Association and Interaction between Heavy Metals and Hyperuricemia in a Taiwanese Population
por: Lu, Lu-Heng, et al.
Publicado: (2023) -
Association of Head and Neck Cancers in Chronic Osteomyelitis: A National Retrospective Cohort Study
por: Tsai, Chia-Ta, et al.
Publicado: (2016)